Exelixis Yönetim

Yönetim kriter kontrolleri 4/4

Exelixis CEO'su Mike Morrissey, Jul2010 tarihinde atandı, in görev süresi 14.33 yıldır. in toplam yıllık tazminatı $ 16.42M olup, şirket hissesi ve opsiyonları dahil olmak üzere 7.3% maaş ve 92.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.55% ine doğrudan sahiptir ve bu hisseler $ 53.17M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 8.5 yıl ve 7.4 yıldır.

Anahtar bilgiler

Mike Morrissey

İcra Kurulu Başkanı

US$16.4m

Toplam tazminat

CEO maaş yüzdesi	7.3%
CEO görev süresi	14.3yrs
CEO sahipliği	0.5%
Yönetim ortalama görev süresi	8.5yrs
Yönetim Kurulu ortalama görev süresi	7.4yrs

Son yönetim güncellemeleri

Recent updates

Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth Engine

Oct 31

Exelixis, Inc.'s (NASDAQ:EXEL) Shares Leap 25% Yet They're Still Not Telling The Full Story

Oct 31

If EPS Growth Is Important To You, Exelixis (NASDAQ:EXEL) Presents An Opportunity

Jun 14

It's Unlikely That Exelixis, Inc.'s (NASDAQ:EXEL) CEO Will See A Huge Pay Rise This Year

May 24

Exelixis' (NASDAQ:EXEL) Strong Earnings Are Of Good Quality

May 07

Exelixis: With Patent Litigation Decision Due Soon, There Are Options

May 02

Exelixis, Inc.'s (NASDAQ:EXEL) Earnings Haven't Escaped The Attention Of Investors

Apr 22

Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024

Mar 28

We Ran A Stock Scan For Earnings Growth And Exelixis (NASDAQ:EXEL) Passed With Ease

Feb 26

Exelixis: Bullish Despite The High Stakes Game Of Cabometyx Patent Battles

Jan 17

Exelixis, Inc.'s (NASDAQ:EXEL) Revenues Are Not Doing Enough For Some Investors

Dec 27

An Intrinsic Calculation For Exelixis, Inc. (NASDAQ:EXEL) Suggests It's 49% Undervalued

May 30

CEO Tazminat Analizi

Mike Morrissey'un ücretlendirmesi Exelixis'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	US$467m
Jun 30 2024	n/a	n/a	US$350m
Mar 31 2024	n/a	n/a	US$205m
Dec 31 2023	n/a	n/a	US$208m
Sep 30 2023	n/a	n/a	US$92m
Jun 30 2023	n/a	n/a	US$164m
Mar 31 2023	n/a	n/a	US$154m
Dec 31 2022	US$17m	US$1m	US$182m
Sep 30 2022	n/a	n/a	US$308m
Jun 30 2022	n/a	n/a	US$273m
Mar 31 2022	n/a	n/a	US$298m
Dec 31 2021	US$8m	US$1m	US$231m
Sep 30 2021	n/a	n/a	US$164m
Jun 30 2021	n/a	n/a	US$94m
Mar 31 2021	n/a	n/a	US$65m
Dec 31 2020	n/a	n/a	US$112m
Sep 30 2020	n/a	n/a	US$152m
Jun 30 2020	n/a	n/a	US$282m
Mar 31 2020	n/a	n/a	US$294m
Dec 31 2019	n/a	n/a	US$321m
Sep 30 2019	n/a	n/a	US$612m
Jun 30 2019	n/a	n/a	US$642m
Mar 31 2019	n/a	n/a	US$650m
Dec 31 2018	n/a	n/a	US$690m
Sep 30 2018	n/a	n/a	US$368m
Jun 30 2018	n/a	n/a	US$323m
Mar 31 2018	n/a	n/a	US$253m
Dec 31 2017	n/a	n/a	US$154m

Tazminat ve Piyasa: Mike 'ın toplam tazminatı ($USD 16.42M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 12.87M ).

Tazminat ve Kazançlar: Mike 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Mike Morrissey (63 yo)

14.3yrs

Görev süresi

US$16,423,307

Tazminat

Dr. Michael M. Morrissey, Ph.D. also known as Mike, serves as Independent Director at XW Laboratories Inc. Dr. Morrissey serves as Independent Chairman of the Board at Vera Therapeutics, Inc since May 24,...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Stelios Papadopoulos	Co-Founder & Chair of the Board	29.9yrs	US$519.97k	0.43% $ 42.3m
Michael Morrissey	CEO, President & Director	14.3yrs	US$16.42m	0.55% $ 53.2m
Christopher Senner	Executive VP & CFO	9.3yrs	US$4.95m	0.16% $ 15.4m
Dana Aftab	Executive VP of Discovery and Translational Research & Chief Scientific Officer	1.9yrs	US$5.65m	0.076% $ 7.4m
Jeffrey Hessekiel	Executive VP & General Counsel	10.8yrs	US$4.56m	0.12% $ 11.8m
Amy Peterson	Executive VP	1.3yrs	US$7.38m	Veri yok
Susan Hubbard	Executive Vice President of Public Affairs & Investor Relations	7.9yrs	Veri yok	Veri yok
Tony Redmond	Senior Vice President of Human Resources	less than a year	Veri yok	Veri yok
Anne Champsaur	Senior Vice President of Drug Safety	9.6yrs	Veri yok	Veri yok
William Berg	Senior Vice President of Medical Affairs	9.2yrs	Veri yok	Veri yok
Patrick Haley	Executive Vice President of Commercial	7.9yrs	US$4.65m	0.049% $ 4.8m
Stefan Krauss	VP & Head of Business Development	no data	Veri yok	Veri yok

8.5yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim: EXEL 'un yönetim ekibi deneyimli ve deneyimlidir ( 8.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Stelios Papadopoulos	Co-Founder & Chair of the Board	29.9yrs	US$519.97k	0.43% $ 42.3m
Michael Morrissey	CEO, President & Director	14.3yrs	US$16.42m	0.55% $ 53.2m
Jack Wyszomierski	Independent Director	20.8yrs	US$490.97k	0.12% $ 11.3m
George Poste	Independent Director	20.3yrs	US$482.22k	0.063% $ 6.1m
Charles Sawyers	Member of the Scientific Advisory Board	no data	Veri yok	Veri yok
Ronald Evans	Member of the Scientific Advisory Board	no data	Veri yok	Veri yok
Sue Eckhardt	Independent Director	less than a year	Veri yok	0% $ 0
Mary Beckerle	Independent Director	less than a year	Veri yok	0% $ 0
Julie Smith	Independent Director	8.2yrs	US$490.92k	0.00027% $ 26.3k
Maria Freire	Independent Director	6.6yrs	US$488.72k	0.025% $ 2.5m
Robert Oliver	Independent Director	1.5yrs	US$717.44k	0.0016% $ 154.9k
Tomas Heyman	Independent Director	1.5yrs	US$716.19k	0.0016% $ 154.9k

7.4yrs

Ortalama Görev Süresi

68yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: EXEL 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.4 yıldır).

Exelixis Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Independent Director notifies of intention to sell stock

CEO, President & Director exercised options and sold US$479k worth of stock

Executive VP notifies of intention to sell stock

Independent Director recently sold US$907k worth of stock

Insider notifies of intention to sell stock

Independent Director recently sold US$576k worth of stock

Recent updates

Investor sentiment improves as stock rises 20%

Independent Director notifies of intention to sell stock

Price target increased by 7.1% to US$31.60

Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth Engine

Exelixis, Inc.'s (NASDAQ:EXEL) Shares Leap 25% Yet They're Still Not Telling The Full Story

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Exelixis, Inc. Reports Impairment of Long-Lived Assets for the Third Quarter Ended September 30, 2024

Here's Why We Think Exelixis (NASDAQ:EXEL) Is Well Worth Watching

Exelixis, Inc. to Report Q3, 2024 Results on Oct 29, 2024

CEO, President & Director exercised options and sold US$479k worth of stock

Executive VP notifies of intention to sell stock

Exelixis, Inc Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine

Getting In Cheap On Exelixis, Inc. (NASDAQ:EXEL) Might Be Difficult

Independent Director recently sold US$907k worth of stock

Consensus EPS estimates increase by 37%

Insider notifies of intention to sell stock

Exelixis Comes Up Aces

Exelixis, Inc. Announces Initiation of Phase 1 Clinical Trial Evaluating XB010 in Patients with Advanced Solid Tumors

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Exelixis, Inc. (NasdaqGS:EXEL) announces an Equity Buyback for $500 million worth of its shares.

Exelixis, Inc. Announces U.S. Food and Drug Administration Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors

Exelixis, Inc. to Report Q2, 2024 Results on Aug 06, 2024

If EPS Growth Is Important To You, Exelixis (NASDAQ:EXEL) Presents An Opportunity

Independent Director recently sold US$576k worth of stock

It's Unlikely That Exelixis, Inc.'s (NASDAQ:EXEL) CEO Will See A Huge Pay Rise This Year

Independent Director notifies of intention to sell stock

Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA

Exelixis' (NASDAQ:EXEL) Strong Earnings Are Of Good Quality

Exelixis: With Patent Litigation Decision Due Soon, There Are Options

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Exelixis, Inc. Reaffirms Earnings Guidance for the Year 2024

Exelixis, Inc.'s (NASDAQ:EXEL) Earnings Haven't Escaped The Attention Of Investors

Exelixis, Inc., Annual General Meeting, May 30, 2024

Exelixis, Inc. to Report Q1, 2024 Results on Apr 30, 2024

Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024

Independent Director notifies of intention to sell stock

Executive Vice President of Commercial recently sold US$1.0m worth of stock

We Ran A Stock Scan For Earnings Growth And Exelixis (NASDAQ:EXEL) Passed With Ease

Executive Vice President of Commercial notifies of intention to sell stock

Full year 2023 earnings: EPS exceeds analyst expectations

Exelixis, Inc. Provides Earnings Guidance for the for Fiscal Year 2024

Exelixis, Inc. Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024

Bristol Myers Squibb and Exelixis, Inc. Announce Four-Year Follow-Up Results from the CheckMate -9ER Trial Evaluating Opdivo (cabozantinib)

Exelixis: Bullish Despite The High Stakes Game Of Cabometyx Patent Battles

Exelixis, Inc. (NasdaqGS:EXEL) announces an Equity Buyback for $450 million worth of its shares.

Exelixis, Inc. (NasdaqGS:EXEL) announces an Equity Buyback for $450 million worth of its shares.

Exelixis, Inc.'s (NASDAQ:EXEL) Revenues Are Not Doing Enough For Some Investors

Executive VP notifies of intention to sell stock

Executive VP notifies of intention to sell stock

Exelixis Announces Initiation of the Stellar-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer

Exelixis, Inc. Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023

Third quarter 2023 earnings released: EPS: US$0.003 (vs US$0.23 in 3Q 2022)

Consensus EPS estimates fall by 10%

Exelixis, Inc. Announces Detailed Results from Phase 3 Cabinet Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023

Exelixis, Inc. to Report Q3, 2023 Results on Nov 01, 2023

CEO, President & Director exercised options and sold US$2.1m worth of stock

Exelixis, Inc. Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors

Exelixis, Inc. Announces Vicki L. Goodman Concludes Her Service as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer

New major risk - Revenue and earnings growth

Executive Vice President of Commercial recently sold US$632k worth of stock

Consensus EPS estimates increase by 11%

Exelixis, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Executive VP notifies of intention to sell stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Exelixis, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Exelixis, Inc. Elects Dave Johnson to its Board of Directors

An Intrinsic Calculation For Exelixis, Inc. (NASDAQ:EXEL) Suggests It's 49% Undervalued

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Exelixis, Inc. Provides Earnings Guidance for the Fiscal Year 2023